123 related articles for article (PubMed ID: 19005745)
1. Cardiovascular outcomes and angiotensin converting enzyme inhibitors: beyond blood pressure control. Editorial to: "Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?" by Remme et al.
Verma A; Ventura HO
Cardiovasc Drugs Ther; 2009 Apr; 23(2):109-11. PubMed ID: 19005745
[No Abstract] [Full Text] [Related]
2. Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?
Remme WJ; Deckers JW; Fox KM; Ferrari R; Bertrand M; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):161-70. PubMed ID: 18931896
[TBL] [Abstract][Full Text] [Related]
3. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure.
Krysiak R; Okopień B
Pharmacol Rep; 2011; 63(5):1151-61. PubMed ID: 22180357
[TBL] [Abstract][Full Text] [Related]
5. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
Ferrari R; Fox K
Drugs; 2009; 69(3):265-77. PubMed ID: 19275271
[TBL] [Abstract][Full Text] [Related]
6. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
[TBL] [Abstract][Full Text] [Related]
7. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
Curran MP; McCormack PL; Simpson D
Drugs; 2006; 66(2):235-55. PubMed ID: 16451098
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari R
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
[TBL] [Abstract][Full Text] [Related]
9. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
[TBL] [Abstract][Full Text] [Related]
11. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
[TBL] [Abstract][Full Text] [Related]
12. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
[TBL] [Abstract][Full Text] [Related]
13. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Deckers JW; Fox KM;
Am Heart J; 2010 May; 159(5):795-802. PubMed ID: 20435188
[TBL] [Abstract][Full Text] [Related]
14. Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials.
Brady AJ
Clin Drug Investig; 2007; 27(3):149-61. PubMed ID: 17305412
[TBL] [Abstract][Full Text] [Related]
15. The EUROPA trial.
Kwaku M; Burman KD; Becker KL; Mannan M
Lancet; 2003 Dec; 362(9399):1935; author reply 1936-7. PubMed ID: 14667758
[No Abstract] [Full Text] [Related]
16. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts JJ; Ferrari R; Simoons ML
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent.
Comini L; Bachetti T; Cargnoni A; Bastianon D; Gitti GL; Ceconi C; Ferrari R
Pharmacol Res; 2007 Jul; 56(1):42-8. PubMed ID: 17475504
[TBL] [Abstract][Full Text] [Related]
19. Divergent effects of angiotensin-converting enzyme inhibition on blood pressure and endothelial function in obese humans.
Williams IL; Chowienczyk PJ; Wheatcroft SB; Patel AG; Sherwood RA; Shah AM; Kearney MT
Diab Vasc Dis Res; 2006 May; 3(1):34-8. PubMed ID: 16784179
[TBL] [Abstract][Full Text] [Related]
20. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Rapezzi C; Ciliberti P; Graziosi M; Riva L
Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
